Left Ventricular Remodeling
Cross-source consensus on Left Ventricular Remodeling from 1 sources and 6 claims.
1 sources · 6 claims
How it works
Comparisons
Evidence quality
Highlighted claims
- Adverse remodeling after myocardial infarction links myocardial injury to progressive heart failure and death. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- Adverse remodeling includes ventricular dilation, hypertrophy, fibrosis, impaired contractility, and worsening systolic function. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- Many trial participants had not yet developed advanced ventricular remodeling at randomization. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- Early enrollment after myocardial infarction may have limited the ability to detect reverse remodeling. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- Existing post-MI therapies mostly reduce neurohormonal activation and hemodynamic load rather than directly targeting myocardial maladaptation. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- More prolonged CDR132L exposure may be needed for maximal remodeling effects based on preclinical data. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial